The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EDSA | -36.47% | -95.08% | -45.25% | -93% |
| S&P | +18.33% | +108.18% | +15.79% | +139% |
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing, and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. The company was founded on June 12, 2007 and is headquartered in Markham, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.03M | 49.8% |
| Market Cap | $14.26M | 3.6% |
| Market Cap / Employee | $0.89M | 0.0% |
| Employees | 16 | 0.0% |
| Net Income | -$1.75M | -4.9% |
| EBITDA | -$1.88M | 0.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $12.36M | 505.7% |
| Accounts Receivable | $0.29M | -48.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | -100.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -59.10% | 35.5% |
| Return On Invested Capital | -157.59% | -48.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.82M | -123.1% |
| Operating Free Cash Flow | -$1.82M | -123.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.04 | 2.75 | 6.60 | 2.24 | -29.51% |
| Price to Tangible Book Value | 18.94 | -55.84 | -10.98 | 3.30 | -47.44% |
| Enterprise Value to EBITDA | -13.99 | -2.71 | -5.10 | -5.92 | -5.53% |
| Return on Equity | -136.7% | -150.7% | -58.8% | -69.6% | -46.14% |
| Total Debt | $0.02M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
